Running Compliant Doctor Surveys at Scale
Almost everything published about surveying doctors is written for markets where paying a physician for forty minutes of their time is an unremarkable commercial transaction. A panel provider holds a pre-recruited sample, an honorarium is set by specialty and length, the invitation goes out, and the fieldwork closes. That model is mature, well documented and largely irrelevant to a pharmaceutical company running research in India, because in India the same payment sits inside a marketing code, a Supreme Court ruling on deductibility and a withholding provision that did not exist before July 2022.
None of that makes doctor research impossible. It makes the standard design expensive, slow and - above a certain sample size - administratively unworkable. The failure is rarely legal. It is that somebody promised ten thousand responses and discovered at the fieldwork stage that ten thousand honoraria means ten thousand consultancy agreements, ten thousand PAN records and ten thousand withholding entries, none of which were in the project plan.
This article works the problem in the order it actually arrives: what the rules permit, what physician response rates really are, where the arithmetic breaks, and how to design a large-sample feedback programme that does not depend on cash at all. It also separates two things the brief for this page ran together - surveying doctors, which is asking, and reverse profiling, which is inferring. They are complements, and confusing them produces research that answers a question nobody had.
How do you survey doctors at scale?
You can pay Indian doctors for survey participation, but only inside a narrow corridor: UCPMP 2024 permits engaging healthcare professionals for bona fide research services under a consultancy agreement with a consultancy fee or honorarium, subject to tax law, while prohibiting gifts, hospitality and monetary grants generally. The practical problem is not legality at small scale - it is that the corridor does not widen. At ten thousand respondents you would need ten thousand consultancy agreements, PAN records and withholding entries. Above roughly a few hundred respondents the honorarium model stops being a compliance question and becomes an operations problem, which is why large-sample doctor feedback in India is better designed without cash incentives at all.
Start by naming the constraint, because it is almost never the questionnaire. Four things gate a large doctor survey, and they gate it in this order.
| Constraint | The question it answers | Why it binds first | What relieves it |
|---|---|---|---|
| 1. The reachable consented base | How many doctors can you lawfully contact through a channel they respond to? | This is the hard ceiling and it is almost always lower than the CRM record count. Duplicates, stale contact details and absent consent all reduce it | Deduplication, contactability verification and a consent capture programme - all of which take quarters, not weeks |
| 2. Response rate | What proportion of those contacted will complete? | Determines the invitation volume required. Published physician rates are lower than most plans assume and have been falling | Shorter instruments, personalised invitation, reminders, relevance of topic |
| 3. The compensation model | Are you paying, and if so under what instrument? | Governs both legality and administrative load. It is the constraint that changes character with scale rather than degree | Designing the programme so that compensation is not load-bearing |
| 4. Instrument design | What are you actually asking? | Matters enormously for data quality and almost not at all for feasibility | Standard research practice |
Most project plans invert this order entirely, starting with the questionnaire and treating the base as an availability problem to be solved later. The base is not solved later. A company with 6,000 consented, contactable, deduplicated doctors cannot produce 10,000 responses at any budget, and no amount of instrument design will change that.
How to collect structured feedback from 10,000 doctors
This is the question buyers actually ask, so here is the arithmetic rather than a methodology lecture. Work backwards from completions and the design constraints become obvious within three lines.
| Step | Calculation | Result | The uncomfortable part |
|---|---|---|---|
| Target completions | Given | 10,000 | - |
| Required invitations at a 35% response rate | 10,000 ÷ 0.35 | ≈ 28,600 | Published web-survey response rates for physician specialists sit around this level, and this is the optimistic branch - achieved on small, pre-identified, academically sponsored samples |
| Required invitations at a 15% rate | 10,000 ÷ 0.15 | ≈ 66,700 | Closer to what an unsolicited commercial invitation to a cold list will achieve. Choose your assumption deliberately and state it |
| Base required after consent and contactability | Invitations ÷ (consent rate × contactability) | Often 1.5–2× the invitation number | This is where most programmes discover the real ceiling. A 40,000-record CRM is not a 40,000-doctor base |
| Honorarium cost at ₹500 per completion | 10,000 × ₹500 | ₹50 lakh | Affordable as a number |
| Consultancy agreements required | One per paid participant | 10,000 | This is the line that ends the discussion. Execution, storage, retrieval on audit, and a PAN and withholding record against each |
| Withholding entries and annual aggregation | Per participant, per financial year | 10,000 | Aggregation across the year is the part that is forgotten. A doctor participating in four studies is one relationship, not four |
Nothing in that table is a legal obstacle. Every line is an operational one, and that is precisely why it does not appear in market-research guidance - the vendor blogs that answer this question today are writing for a market where the payment is a transaction, not an engagement.
The conclusion follows directly. At fifty doctors, pay them properly under a consultancy agreement and do it carefully. At ten thousand, do not build the programme on cash at all - build it on channels the doctor has already consented to, instruments short enough not to require compensation, and a base large enough that a lower response rate still clears the target. The rest of this article is how.
What physician response rates actually are
Response-rate planning assumptions are usually inherited rather than sourced, and they are usually too high. The published evidence is worth stating precisely, including its limitations, because the limitations are what make it applicable.
| Finding | Figure | Source and design | How to read it |
|---|---|---|---|
| Web-based survey of physician specialists, overall | 35.0% (317 of 904) | Six specialties, one Canadian metropolitan area, administered 2009, with multiple follow-up reminders | An upper bound for a commercial programme, not a target. Pre-identified sample, academic sponsorship, personalised invitations |
| By specialty | Neurology and neurosurgery 46.6%; internal medicine 42.9%; general surgery 29.6%; paediatrics 29.2%; psychiatry 27.1% | Same study | A 19-point spread across specialties. A single blended assumption will over-deliver on some cells and fail on others - plan the quota by specialty |
| Postal comparison | ~49.6% average among specialists in prior research | Cited comparison | Postal historically outperformed web. Largely academic interest now, but it tells you the channel effect is real and large |
| Incentive experiment | $25 incentive → 48.0%; $50 incentive → 52.4% | Randomised, 500 internal medicine physicians, 250 per arm | Doubling the incentive bought 4.4 percentage points. The most useful single fact in this section |
| Cost per completion in that experiment | $154.22 at $25 versus $208.01 at $50 | Same experiment | The higher incentive raised cost per completion by about 35% to buy a 4.4-point gain. Incentive is a weak lever and an expensive one |
| The same programme before the pandemic | 62.6% in 2018; 59.3% in 2019 | Same research series | Rates were already falling before incentives were varied. Do not plan on historical benchmarks from another decade |
| Main barrier cited by non-respondents | 60.3% cited lack of time or survey burden | Same specialist study | Length is the lever that works. It is also free, unlike incentive |
| Self-reported participation | Physicians report participating in fewer than half the studies they are invited to | Panel-provider research, Canadian physicians, 2022; the provider notes real response is lower still | A panel relationship does not solve the response problem, it only makes the base addressable |
Two cautions on all of the above. These are North American studies on small, pre-identified samples with academic sponsorship - the most favourable conditions available. And none of them measure what an Indian commercial invitation to a cold list achieves, because that figure is not published by anyone. Use the published rates to bound the optimistic case, and measure your own within the first thousand invitations rather than assuming.
The practical reading is that length beats money. Sixty per cent of non-respondents cited burden; doubling the cash bought four points. A ten-question instrument that takes three minutes will outperform a forty-question instrument with an honorarium attached, and it will do so without any of the compliance apparatus the next section describes.
The honorarium question: what UCPMP 2024 permits
This section is a summary of published legal analysis, not legal advice, and the article says so deliberately. Every point below should be confirmed with counsel against the notified text before it governs a live programme. What follows is the shape of the corridor as practitioners currently understand it.
The Uniform Code for Pharmaceutical Marketing Practices 2024 was brought in by the Department of Pharmaceuticals with a stated intent of strict implementation, and it is administered through an Ethics Committee for Pharma Marketing Practices with a complaint window and a schedule of consequences. Its general posture toward payments is restrictive; its treatment of research services is the exception that makes doctor surveys possible at all.
| Provision area | What it says | What it means for a survey |
|---|---|---|
| Consultant and advisory engagement | Companies may engage healthcare professionals in a consultant or advisory capacity for **bona fide research services, under a consultancy agreement, involving a consultancy fee or honorarium-based payment, subject to compliance with all applicable tax laws** | This is the entire legal basis for paying a doctor to take part in research. Three conditions travel together - bona fide research, a consultancy agreement, and tax compliance. Dropping any one of them collapses the exemption |
| General prohibition | No gifts or benefits to healthcare professionals or their family members, including any form of pecuniary advantage, travel arrangements, hospitality or monetary grants | A payment that is not structured as a fee for bona fide research services is a pecuniary advantage. The instrument is what distinguishes the two, which is why the consultancy agreement is not paperwork - it is the thing being relied on |
| Brand reminders | Permitted only for items of professional use valued under ₹1,000, with tax reporting obligations on both giver and recipient | A voucher, gift card or product as a thank-you is a brand reminder at best and a prohibited benefit at worst. The North American gift-card incentive model does not transfer |
| Continuing medical education | Event details and expenditure to be published on the company website, subject to independent audit; foreign-location events prohibited | Not directly a survey provision. It establishes the disclosure posture - the direction of travel is toward publishing what you spent and on whom |
| Enforcement | Ethics Committee for Pharma Marketing Practices handles complaints within a six-month filing window; consequences include suspension, expulsion, reprimand and corrective statements | The corrective-statement remedy is the commercially significant one. It is a public finding, and it lands on the brand rather than on an individual |
The test to apply to your own study Before any payment is approved, three questions should have documented answers. Is this bona fide research - would the study be commissioned even if no commercial relationship existed with the respondent? Is the payment made under a consultancy agreement that describes a service, a deliverable and a fee? And is the fee proportionate to the time and expertise involved rather than to the respondent's prescribing value? The third question is the one that separates research from inducement in substance rather than in form. A payment that scales with how much a doctor prescribes is not a consultancy fee whatever the agreement says. A payment that scales with the length of the instrument is. |
The tax layer nobody models
The compliance conversation about doctor payments almost always stops at the marketing code. The tax position is at least as consequential and is settled law in a way the code is not.
Apex Laboratories: deductibility
In 2022 the Supreme Court held in Apex Laboratories Pvt Ltd v Deputy Commissioner of Income Tax that expenditure on freebies to doctors is not deductible business expenditure. The reasoning ran through Explanation 1 to Section 37(1) of the Income-tax Act, which disallows deductions for expenditure that constitutes an offence or is prohibited by law, read together with Regulation 6.8 of the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002, which prohibits doctors from accepting gifts, travel facilities, hospitality, cash or monetary grants from a pharmaceutical company.
The Court's move was to hold that prohibiting acceptance implicitly prohibits provision, and that allowing a deduction would sustain what it described as a publicly injurious cycle. The commercial consequence is direct: a payment characterised as a prohibited benefit is not merely a compliance exposure, it is a non-deductible cost.
What the judgment did not decide It addressed prohibited freebies. It did not draw the line between a freebie and a legitimate fee for a genuine service. That silence is the whole difficulty for market research. A consultancy fee for bona fide research is, on the face of the marketing code, a permitted engagement - but the judgment offers no test for when a payment stops being a fee and becomes an inducement in substance. The practical posture is therefore to build the documentation you would want if that question were asked: what was commissioned, what was delivered, how the fee was set, and why it bears no relationship to prescribing. This is an area where counsel should be involved before the first payment, not after the first complaint. |
Section 194R: withholding
Since 1 July 2022, Section 194R has required any person responsible for providing a benefit or perquisite to a resident to withhold tax at 10%, and the CBDT's guidance in Circular No. 12/2022 dated 16 June 2022 made clear that the payer is not required to establish the taxability of the amount in the recipient's hands before deducting.
For a survey programme that matters in two ways. First, if compensation is provided in kind rather than in cash - a voucher, a device, a subscription - it is squarely a benefit or perquisite, and the withholding obligation attaches to something that has no cash flow to deduct from. Second, a cash consultancy fee is ordinarily professional income, which brings its own withholding regime and, with it, PAN collection, deduction, deposit, return filing and certificate issue for every participant.
| Compensation design | Likely characterisation | Administrative load per participant | Practical verdict at scale |
|---|---|---|---|
| Cash consultancy fee under an agreement | Professional fee for bona fide research services | Agreement, PAN, withholding, deposit, return, certificate, annual aggregation | Defensible and correct - and roughly seven artefacts per respondent. Workable to a few hundred |
| Voucher or gift card | Benefit or perquisite, and possibly a prohibited gift under the code | Withholding with no cash to deduct from, plus a brand-reminder problem | Avoid. It imports the marketing-code risk and the tax problem simultaneously |
| Charitable donation in the doctor's name | Unsettled | Varies | Common workaround, genuinely unclear. Confirm with counsel; do not adopt it because it feels safer |
| Prize draw or lottery | Benefit or perquisite; separate gaming and prize-tax considerations | Concentrated but non-trivial | Research evidence also shows lotteries underperform small individual payments on response. Weak on both counts |
| No compensation | Not a payment | None | The only design that scales cleanly, and the one this article recommends above a few hundred respondents |
Why the honorarium model breaks at scale
Put the three strands together and the break point becomes visible. It is not a legal threshold - nothing changes in the rules between the hundredth doctor and the thousandth. It is the point at which per-respondent administration overwhelms the research.
| Sample size | What the honorarium model looks like | Assessment |
|---|---|---|
| Up to ~50 | Individually negotiated consultancy agreements, named deliverables, proper fees, full documentation | The model works as designed. This is what the exemption contemplates - genuine advisory engagement |
| 50–300 | Templated agreements, standardised fee by specialty and instrument length, a managed collection process for PAN and withholding | Workable with dedicated operational support. The documentation burden is real but bounded |
| 300–1,000 | Process becomes the project. Agreement execution and tax administration consume more effort than fieldwork | The break point sits in this band for most organisations. The research question stops driving the design |
| Above 1,000 | Thousands of agreements, PAN records and withholding entries, with annual aggregation across studies | Do not attempt on an honorarium basis. The failure will be administrative and it will surface at the worst moment, which is audit |
| 10,000 | - | Structurally the wrong design. See the next section for what replaces it |
One further point that is easy to miss and expensive to discover. Aggregation runs across studies, not within them. A doctor who participates in four studies in a financial year is one relationship with one cumulative position, and the organisation is expected to see it as one. A company running multiple brand studies through multiple agencies frequently cannot - which means the aggregate exposure exists and is invisible. That is an argument for centralising doctor research under one register regardless of what the compensation model is.
Designing for scale without cash incentives
If compensation cannot carry a ten-thousand-respondent programme, something else has to. Five design moves do the work, and they compound.
- Shorten the instrument until compensation is not warranted. Sixty per cent of non-respondents in the published research cited time and burden. Three questions answered in ninety seconds sits in a different psychological category from a forty-minute study, and it needs no fee to be reasonable. Ask three things well rather than thirty things badly.
- Embed in channels the doctor already uses and has consented to. A question at the end of a rep interaction, inside a portal session, or in a messaging thread the doctor opted into performs differently from a cold email, because the relationship already exists. The consent is already captured and the channel is already proven - both of the first two constraints are relieved at once.
- Distribute the instrument across time rather than asking everything at once. Three questions a quarter to the same doctor yields twelve data points a year at a fraction of the perceived burden of one long study. This is the single most underused design in pharmaceutical insights work, and it produces something a one-off study cannot: a series.
- Give a reason to answer that is not money. Early access to a summary of what peers said, a benchmark of their own practice against the aggregate, or a genuine influence on something the company will do. Reciprocity is not a payment and does not attract either regime - but it has to be real, and the summary has to actually arrive.
- Accept a lower response rate and widen the base. A 6% response rate on a consented base of 200,000 produces 12,000 completions. A 45% response rate on a base of 12,000 produces 5,400. The base is the lever with the larger exponent, and it is also the asset that persists after the study closes.
The fifth point is the one that changes what a company should be investing in. A large, clean, consented, contactable doctor base is not merely a marketing asset. It is the precondition for ever being able to ask anything at scale, and it takes far longer to build than any individual study takes to run.
Reverse profiling, and how survey data feeds it
The brief for this page pairs doctor surveys with reverse profiling, and the pairing is worth taking apart because the two are routinely confused. Reverse profiling infers the characteristics of the doctors most likely to prescribe, working backwards from existing data - practice demographics, prescribing and sales patterns, digital engagement behaviour - to describe a target profile. The definition, the use cases and the technique are set out on the live reverse profiling in pharma page and this article does not restate them.
The distinction that matters here is between asked data and observed data. Reverse profiling runs on observed data: what doctors did. A survey produces asked data: what doctors say. They fail in different directions, and that is precisely what makes them useful together.
| Observed data | Asked data | |
|---|---|---|
| What it is | Behaviour recorded as it happened - engagement, response, sales movement, digital activity | Stated responses to questions |
| Its strength | It happened. No recall error, no social desirability, no self-selection into the sample | It can answer why. Intent, barrier, perception and awareness are not inferable from behaviour |
| Its weakness | It cannot explain itself. A doctor who stopped engaging looks identical to a doctor whose email address changed | Small, self-selected samples and stated preference that may not predict behaviour |
| Coverage | Everyone in the base, continuously | A responding subset, at a point in time |
| Cost per doctor | Near zero once the pipeline exists | Material, in money or in goodwill |
| The right job | Scoring, targeting, prioritisation, monitoring - anything needing full coverage | Calibration, explanation, hypothesis testing - anything needing a reason |
The productive relationship is calibration, and it runs in one direction more often than people expect. A reverse-profiling model produces a target profile from observed patterns. A short survey to a sample inside and outside that profile tests whether the model is picking up what it thinks it is picking up - or whether it has found a data artefact, which is the more common outcome. Survey the model's edges, not its centre. The doctors the model is confident about teach you nothing; the ones it places near the boundary are where the profile is either validated or falsified.
The inverse also works and is cheaper. Ask a small sample a question you could in principle observe, then check whether your observed data agrees. Where it does, you have licensed yourself to use the observed proxy across the whole base without asking again. That is how a three-question survey to 400 doctors becomes a usable attribute on 200,000 - and it is a far better use of a survey than trying to reach 10,000 people with the same instrument.
GET ACTIONABLE AI AND HEALTHCARE INSIGHTS THAT HELP YOU STAY AHEAD IN A FAST-CHANGING PHARMA WORLD
DPDP and survey data: the trap is reuse
Survey responses from a doctor are personal data and the doctor is the data principal. That much is straightforward and the programme has covered the framework across several live pages. The specific trap for research is purpose limitation, and it catches good organisations rather than careless ones.
| Requirement | What it means for a survey | The failure mode |
|---|---|---|
| Notice and purpose specification | The notice must state what data is processed and for what purpose, in clear terms, with rights explained | A notice written for research purposes does not cover commercial targeting. The wording at the point of collection is the ceiling on everything downstream |
| Purpose limitation | Data collected for research may be used for research | The trap. A study identifies doctors with a stated barrier to prescribing; six months later a brand team wants to target them. That is a new purpose and the original notice almost certainly does not support it |
| Consent standard | Free, specific, informed, unconditional, unambiguous, through clear affirmative action. Pre-ticked boxes are not valid | Bundling research consent into a general marketing opt-in fails the specificity test and contaminates both |
| Data minimisation | Collect what the purpose requires | Long instruments that capture attributes ‘while we have them’. The extra questions are the ones that create exposure without creating value |
| Retention and erasure | Erasure within 90 days of a data principal request; retention tied to purpose | Research datasets are the ones that never get deleted, because they live in analyst files rather than in systems with lifecycle controls |
| Anonymisation as the escape route | Data that is genuinely anonymised is outside the regime | ‘De-identified’ is not ‘anonymised’. A dataset of 400 doctors with specialty, city and practice type is re-identifiable and should be treated as personal data |
The practical rule is to decide the downstream use before collection, not after. If survey findings will inform targeting, the notice has to say so at the point of collection and the consent has to be specific to it - which will reduce participation, and should. The alternative is a dataset that is valuable and unusable, which is the worst outcome available and a surprisingly common one.
One design note that resolves most of this. Aggregate findings - ‘38% of cardiologists in tier-two cities cite formulary access as the primary barrier’ - carry almost all of the research value and none of the individual-level exposure. Build the programme to produce aggregate insight by default and individual-level attributes only where a specific, notified purpose requires them. Most insights functions discover, when they check, that they never needed the individual-level data at all.
A worked design for 10,000 responses
The design below is illustrative and constructed for this article, to show what replaces the honorarium model at scale. The figures are modelled rather than observed and should be rebuilt on your own base. What transfers is the structure, not the numbers.
Objective: 10,000 structured responses from Indian doctors across three therapy areas within one financial year, without individual compensation, and defensible under both the marketing code and DPDP.
| Component | Design decision | Contribution | Why it works |
|---|---|---|---|
| Base | Consented, deduplicated, contactability-verified doctor base of ~120,000 | The ceiling on everything | Built once, reused indefinitely. This is the asset; the study is the application |
| Instrument | Three questions, under 90 seconds, therapy-area specific | Removes the case for compensation | Sixty per cent of non-respondents cite burden. Length is the free lever |
| Channel | Embedded in existing consented touchpoints - rep interaction close, portal session, opted-in messaging | Lifts response materially over cold email | Consent and contactability already proven. Two constraints relieved at once |
| Cadence | One micro-survey per doctor per quarter, rotating question sets | Four opportunities per doctor per year | Produces a time series rather than a snapshot, at lower perceived burden than one long study |
| Response assumption | 6% per invitation - deliberately pessimistic for an unsolicited commercial micro-survey | - | Plan pessimistic, measure early. Revise after the first thousand invitations, not after the study |
| Arithmetic | 120,000 × 4 quarters × 6% = 28,800 responses, of which ~10,000 usable after quality screening and quota balancing | Target met with headroom | The headroom is what absorbs a wrong response assumption |
| Reciprocity | Quarterly aggregate benchmark returned to every participant | Lifts repeat participation | Not a payment; attracts neither regime. It must actually be sent |
| Compensation | None | Removes ~10,000 agreements, PAN records and withholding entries | The entire administrative load disappears |
| Deep-dive supplement | 40–60 doctors on proper consultancy agreements for qualitative depth | Explains what the micro-surveys surface | This is where the honorarium model belongs - at the scale the exemption contemplates |
| Governance | One central register of all doctor research across brands and agencies | Makes aggregate exposure visible | Required whatever the compensation model, and almost never in place |
Two features of this design are worth stating explicitly because they are the ones that get edited out. The pessimistic response assumption is deliberate - a design that only works at 35% is a design that fails, and one that works at 6% will comfortably over-deliver if the true rate is higher. And the forty to sixty deep-dive interviews are not a consolation prize for the doctors who were not paid. They are the qualitative spine, and the micro-survey programme exists partly to tell you which forty doctors to talk to.
What this design cannot do is produce a representative probability sample, and a research professional will say so immediately. It produces a large, continuously refreshed, self-selected sample with known and measurable bias - which, weighted against the known structure of the base, answers most commercial questions better than a small representative sample answers them once a year. Say which of the two you are building, and do not claim the properties of the other.
Where doctor survey programmes fail
| Failure | What it looks like | The correction |
|---|---|---|
| Designing the instrument before sizing the base | A forty-question study approved, then fieldwork discovers 9,000 contactable consented doctors against a 10,000 target | Size the base first, always. It is the only constraint that cannot be relieved inside a project timeline |
| Treating the CRM record count as the base | 40,000 records, of which perhaps half are unique, current and consented | Deduplicate and verify contactability before quoting a number to anyone. The gap is routinely 40–60% |
| Inheriting a response-rate assumption | A 30% plan assumption borrowed from an academic study on a pre-identified sample | Measure on the first thousand invitations and re-plan. State the assumption and its source in the plan document |
| Compensating in kind because cash felt risky | Gift vouchers issued, which are both a possible prohibited benefit and a withholding event with no cash to deduct from | In-kind is worse, not safer. If you are paying, pay a fee under an agreement; if you cannot, do not pay |
| Fragmented research across agencies | Four brand teams commission four studies; the same doctor appears in three; nobody can see the aggregate | One central register of doctor research. This is a governance fix, not a systems project |
| Purpose creep | Research data reused for targeting six months later under a notice that never contemplated it | Decide the downstream use before collection. Retrofitting consent is not available |
| Individual-level data collected by default | Attributes captured per doctor when the finding needed was aggregate | Default to aggregate. Collect individual-level attributes only against a specific notified purpose |
| Reporting a self-selected sample as representative | ‘38% of cardiologists’ when it is 38% of cardiologists who chose to answer | Say which it is. The finding is still useful; the overclaim is what destroys its credibility internally |
What changes in India
| Difference | What it changes | Practical implication |
|---|---|---|
| The compensation corridor is narrower | UCPMP 2024, the Apex Laboratories position on deductibility and Section 194R all apply to the same payment | Three regimes, one transaction. A design that clears only the marketing code is not cleared |
| Panel infrastructure is thinner | Pre-recruited, compensated physician panels of the scale available in North America and Europe do not exist equivalently | You are building the base, not renting it. Budget and plan on that basis |
| Prescriber-level behavioural data is scarce | The observed-data side of the asked-versus-observed pairing is weaker, which raises the relative value of asking | Surveys carry more weight here than in markets with prescriber-level panels, which is an argument for building the capability properly |
| Channel behaviour differs | Messaging channels outperform email with Indian doctors by a wide margin where consent exists | Design for the channel your base actually responds on, and measure by channel rather than in aggregate |
| Language and region | A single-language instrument narrows the effective base, and notice obligations contemplate availability in the constitutional languages on request | Micro-surveys are cheap to translate; long instruments are not. Another argument for three questions |
| Specialty concentration | Response rates vary by nearly twenty points across specialties in the published evidence | Set quotas by specialty and plan invitation volume per cell, not in aggregate |
Where Multiplier AI fits - and where it does not
Disclosure Multiplier AI builds and maintains consented doctor bases and engagement channels, which is the asset this article argues is the binding constraint. That is a conflict worth naming: an article concluding that the base matters more than the study is an article that favours what we sell. We have written it anyway because the arithmetic is checkable and because the alternative conclusion - that a large honorarium budget solves the problem - is the one that fails in practice. A reader who builds the base themselves and never buys anything from us has still reached the right answer. |
Where we fit is the first constraint and the third. The GenAI Doctor Data Platform exists to produce the resolved, consented, contactable base that any large-sample programme depends on, and the doctor mobile and email platform is the channel layer that makes a micro-survey reach someone. Neither is a research capability and we do not present them as one.
Where we do not fit is research design. Questionnaire construction, sampling strategy, qualitative moderation and the interpretation of findings are a specialist discipline, and a company that is good at data infrastructure is not automatically good at asking questions well. For a study that will inform a significant commercial decision, a research partner is the right answer and we will say so.
And where we are the wrong choice outright: a company that needs a representative probability sample with published methodology, and a company whose research is regulatory or clinical rather than commercial. Both call for a research house with the relevant accreditation, and the compliance posture in those contexts is materially different from the one described here.
Conclusion
The question this page was written to answer - how do you collect structured feedback from ten thousand doctors - has an answer, but not the one the question implies. You do not do it by finding ten thousand doctors willing to complete a study for a fee. The corridor that makes paying a doctor lawful in India is real and usable, and it was designed for genuine advisory engagement at the scale genuine advisory engagement happens: dozens, not thousands.
At ten thousand the design has to change shape entirely. Three questions instead of forty, embedded in a channel the doctor already accepted, repeated quarterly, returned with something the doctor actually wanted, and run against a base large enough that a poor response rate still clears the number. None of that requires a payment, which means none of it requires an agreement, a PAN record or a withholding entry - and the compliance problem that dominates the conventional design simply does not arise.
What it does require is the base, and the base takes years. That is the genuinely uncomfortable finding in this article: the capability to ask ten thousand doctors anything is not something a research budget can buy in a quarter. It is an accumulated asset, built from consent captured one interaction at a time, maintained continuously, and worth considerably more than any single study run against it.
Frequently Asked Questions For Doctor Surveys in Pharma
Yes, within a narrow corridor. *UCPMP 2024 permits engaging healthcare professionals in a consultant or advisory capacity for bona fide research services, under a consultancy agreement, involving a consultancy fee or honorarium-based payment, subject to compliance with all applicable tax laws. Outside that structure, payments and benefits to healthcare professionals - including pecuniary advantage, hospitality and monetary grants - are prohibited. The three conditions travel together: genuine research, a written consultancy agreement, and tax compliance. This is a summary of published analysis and not legal advice; confirm the position with counsel before any payment.*
Not by paying them. At ten thousand respondents an honorarium model requires ten thousand consultancy agreements, PAN records and withholding entries, with annual aggregation across studies - an administrative load that overwhelms the research somewhere between 300 and 1,000 participants. The design that scales is a three-question instrument under ninety seconds, embedded in channels the doctor has already consented to, repeated quarterly against a large consented base, with an aggregate benchmark returned to participants instead of a fee. On a base of 120,000 with a pessimistic 6% response rate across four waves, that yields roughly 28,800 responses.
Lower than the published figures, and measure your own early. A web-based survey of physician specialists recorded 35.0% overall, ranging from 27.1% in psychiatry to 46.6% in neurology - but that was a small, pre-identified, academically sponsored sample with personalised invitations and multiple reminders, which is the most favourable case available. An unsolicited commercial invitation to a cold list will do considerably worse. Plan pessimistically, set quotas by specialty because the spread is nearly twenty points, and revise after the first thousand invitations.
Marginally, and expensively. In a randomised experiment on 500 internal medicine physicians, a $25 incentive produced a 48.0% response rate and a $50 incentive 52.4% - 4.4 percentage points - while cost per completion rose from $154.22 to $208.01. By contrast, 60.3% of non-respondents in a separate specialist study cited lack of time or survey burden as their reason. Shortening the instrument is a stronger lever than raising the fee, and it costs nothing.
They are different and complementary. Reverse profiling works backwards from existing data - practice demographics, prescribing and sales patterns, digital engagement - to infer the characteristics of the doctors most likely to prescribe a product. A survey asks doctors directly. Reverse profiling runs on observed data and covers everyone in the base continuously; a survey produces asked data from a responding subset at a point in time. The productive combination is to use a short survey to calibrate the model at its boundary cases, where the profile is either validated or falsified.
Only if the notice at the point of collection said so and the consent was specific to it. Under the DPDP framework, consent must be free, specific, informed, unconditional and unambiguous, and purpose limitation means data collected for research may be used for research. A study that identifies doctors with a stated barrier, followed six months later by a brand team wanting to target them, is a new purpose. Decide the downstream use before collection - retrofitting consent is not available - and default to aggregate findings, which carry most of the research value and none of the individual-level exposure.
No - they are worse on both regimes simultaneously. A voucher or gift card is a benefit or perquisite, which brings Section 194R withholding into play with no cash flow to deduct from, and it sits closer to the prohibited-gift category under the marketing code than a documented consultancy fee does. If you are compensating, do it as a fee for a described service under an agreement. If that is not workable at your sample size, do not compensate at all and redesign the study.
Yes, and most organisations do not have one. Tax aggregation runs across studies within a financial year, not within a single study, so a doctor participating in four brand studies through three agencies is one cumulative relationship that nobody can currently see. A single register of all doctor research across brands and agencies makes that exposure visible. It is a governance fix rather than a systems project, and it is required whatever the compensation model turns out to be.
GET ACTIONABLE AI AND HEALTHCARE INSIGHTS THAT HELP YOU STAY AHEAD IN A FAST-CHANGING PHARMA WORLD
Let's Discuss Your Requirements
